These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25824731)

  • 21. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.
    Cloyd JM; Poultsides GA
    World J Gastroenterol; 2015 Aug; 21(32):9512-25. PubMed ID: 26327759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of neuroendocrine tumors.
    Chung C
    Am J Health Syst Pharm; 2016 Nov; 73(21):1729-1744. PubMed ID: 27769969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine tumors of the pancreas.
    Milan SA; Yeo CJ
    Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
    Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
    World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment options for PNET liver metastases: a systematic review.
    Nigri G; Petrucciani N; Debs T; Mangogna LM; Crovetto A; Moschetta G; Persechino R; Aurello P; Ramacciato G
    World J Surg Oncol; 2018 Jul; 16(1):142. PubMed ID: 30007406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
    QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Strosberg J; Goldman J; Costa F; Pavel M
    Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
    Broder MS; Chang E; Reddy SR; Neary MP
    Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.